BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.
- HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.
- The DPX™ antigen delivery platform acquired by BioVaxys is designed to stimulate a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers.
- These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function.
- Findings showed clinical benefit to patients with recurrent ovarian cancer, regardless of platinum sensitivity or BRCA mutational status.